Karyopharm Therapeutics Inc. is a clinical-stage pharmaceutical company focused on the discovery and development of novel cancer therapies. With a deep pipeline of innovative drug candidates, including the FDA-approved oral therapy Xpovio, the company is at the forefront of advancing treatments for patients with hard-to-treat cancers.
